Operates as a BSE-listed chemicals trading business, generating essentially all revenue from a single Chemical Business segment, alongside a perfume line that is too small to register. FY26 consolidated revenue stood at Rs 144.02 crore, up 51.2% year-on-year, while consolidated net profit fell 12.7% to Rs 2.4757 crore. Standalone revenue for FY26 was Rs 7,588.76 lakhs with standalone net profit of Rs 153.79 lakhs. The cost shape is light: materials cost 28.6% of revenue, employee cost 0.6%, and capex 0.6%, consistent with a trading rather than manufacturing model. EBITDA margin is thin at 3.3% of revenue. The company carries a subsidiary, Yasons Chemex Care Limited, which reported a Rs 70 lakh loss in Q4 FY26. Day-to-day operations are run by promoter-directors Pritesh Shah (Managing Director) and Dimple Shah (Whole-Time Director). AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Chemical Business (100%), Perfume Business (0%). Asset-light chemical trading with thin margins
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 98 | 85 | 95 | 95 | 144 |
| EBITDA (ex other income) | 4 | (0) | (0) | 3 | 1 |
| margin % | 3.7 | (0.1) | (0.0) | 3.5 | 0.8 |
| Owners' profit | 3 | 0 | (0) | 3 | 2 |
| EPS, as reported (₹) | 3.33 | 2.73 | (0.27) | 2.01 | 1.97 |
| ROE % · ROCE % | 9.9 · 14.9 | 10.4 · 14.5 | 0.6 · 2.6 | 4.9 · 9.1 | 4.0 · 7.3 |
| Debt / equity (x) | 0.29 | 0.29 | 0.18 | 0.21 | 0.25 |
| Cash from operations | (3) | 5 | (18) | (1) | 0 |
| Capex | (0) | (3) | (0) | (0) | (1) |
| ₹ crore | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 14 | 24 | 27 | 30 | 30 | 39 | 34 | 41 |
| Profit before tax | 2 | 1 | (0) | 1 | 1 | 1 | 1 | (0) |
| Net profit | 1 | 1 | 0 | 0 | 1 | 1 | 1 | (0) |
| EPS (₹) | 0.93 | 0.60 | 0.28 | 0.20 | 0.57 | 0.68 | 0.82 | 0.10 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| UNIPHOS ENTERPRISES LTD | 635 | 31.4 | 0.26 | — | 0.8 | 0.8 | — | — |
| VINYL CHEMICALS (I) LTD. | 402 | 17.3 | 3.09 | — | 12.7 | 16.8 | — | 9.0 |
| EVEXIA LIFECARE LIMITED | 310 | 55.0 | 0.71 | 108.2 | 0.4 | 0.3 | 0.7 | 3.3 |
| BHAVIK ENTERPRISES LIMITED | 293 | 19.8 | — | — | — | 11.1 | — | — |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 11 Sept 2026 · Promoter buys 3,000 shares of Yash Chemex via open market | ownership changes | low | — | — |
| 9 Sept 2026 · Promoter Paxal Shah buys 2,000 shares in Yash Chemex via open market | ownership changes | low | — | — |
| 4 Sept 2026 · Newspaper publication for 20th AGM and e-voting notice | compliance | minimal | — | — |
| 3 Sept 2026 · Annual Report 2025-26 filed; AGM on Sep 30, 2026 | results | high | — | — |
| 3 Sept 2026 · Notice of 20th AGM on September 30, 2026 | board shareholder meetings | low | — | — |
| 27 Aug 2026 · Promoter Paxal Shah buys 1600 shares of Yash Chemex via open market | ownership changes | low | — | — |
| 21 Aug 2026 · Promoter Paxal Shah buys 3,500 shares of Yash Chemex via open market | ownership changes | low | — | — |
| 11 Aug 2026 · Postal Ballot: TRS and Associates appointed as Statutory Auditor | board shareholder meetings | medium | — | — |
| 11 Aug 2026 · Postal ballot results: new statutory auditor appointed | compliance | minimal | — | — |
| 31 Jul 2026 · Board meeting on 14 Aug 2026 to consider Q1 FY27 results | results | low | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A-1 LIMITED |
| 289 |
| 26.2 |
| 5.34 |
| 26.2 |
| 11.1 |
| 14.8 |
| — |
| 3.5 |
| SHANKAR LAL RAMPAL LTD | 245 | 13.3 | 2.00 | — | 11.0 | 14.7 | — | 9.4 |
| MYSORE PETRO CHEMICALS L | 93 | 17.1 | 0.41 | 100.3 | 0.4 | 0.2 | 18.0 | (0.4) |
| Yash Chemex Limited ◆ | 53 | 24.1 | 0.87 | 14.4 | 4.0 | 5.2 | 20.6 | (0.0) |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 24.1 | 17.2 | 11 of 14 | 23% |
| P/B | 0.9 | 0.8 | 6 of 10 | 44% |
| ROCE | 5.2 | 3.0 | 7 of 14 | 54% |
| ROE | 4.0 | 0.8 | 4 of 10 | 67% |
| Debt / Equity | 0.3 | 0.0 | 8 of 10 | 22% |
| EBITDA margin | (0.0) | 3.3 | 7 of 9 | 25% |
| Revenue growth | 36.8 | 10.9 | 5 of 11 | 60% |
| Profit growth | (199.5) | 5.7 | 9 of 10 | 11% |
| Market cap | 53 | 93 | 8 of 13 | 42% |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
